Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1 : An analysis of 1690 patients from the acute leukemia working party of EBMT

Show full item record



Permalink

http://hdl.handle.net/10138/206990

Citation

Canaani , J , Beohou , E , Labopin , M , Socie , G , Huynh , A , Volin , L , Cornelissen , J , Milpied , N , Gedde-Dahl , T , Deconinck , E , Fegueux , N , Blaise , D , Mohty , M & Nagler , A 2017 , ' Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1 : An analysis of 1690 patients from the acute leukemia working party of EBMT ' , American Journal of Hematology , vol. 92 , no. 4 , pp. 344-350 . https://doi.org/10.1002/ajh.24640

Title: Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1 : An analysis of 1690 patients from the acute leukemia working party of EBMT
Author: Canaani, Jonathan; Beohou, Eric; Labopin, Myriam; Socie, Gerard; Huynh, Anne; Volin, Liisa; Cornelissen, Jan; Milpied, Noel; Gedde-Dahl, Tobias; Deconinck, Eric; Fegueux, Nathalie; Blaise, Didier; Mohty, Mohamad; Nagler, Arnon
Contributor: University of Helsinki, Clinicum
Date: 2017-04
Language: eng
Number of pages: 7
Belongs to series: American Journal of Hematology
ISSN: 0361-8609
URI: http://hdl.handle.net/10138/206990
Abstract: The French, American, and British (FAB) classification system for acute myeloid leukemia (AML) is extensively used and is incorporated into the AML, not otherwise specified (NOS) category in the 2016 WHO edition of myeloid neoplasm classification. While recent data proposes that FAB classification does not provide additional prognostic information for patients for whom NPM1 status is available, it is unknown whether FAB still retains a current prognostic role in predicting outcome of AML patients undergoing allogeneic stem cell transplantation. Using the European Society of Blood and Bone Marrow Transplantation registry we analyzed outcome of 1690 patients transplanted in CR1 to determine if FAB classification provides additional prognostic value. Multivariate analysis revealed that M6/M7 patients had decreased leukemia free survival (hazard ratio (HR) of 1.41, 95% confidence interval (CI), 1.01-1.99; P = .046) in addition to increased nonrelapse mortality (NRM) rates (HR, 1.79; 95% CI, 1.06-3.01; P = .028) compared with other FAB types. In the NPM1(wt) AML, NOS cohort, FAB M6/M7 was also associated with increased NRM (HR, 2.17; 95% CI, 1.14-4.16; P = .019). Finally, in FLT3-ITD+ patients, multivariate analyses revealed that specific FAB types were tightly associated with adverse outcome. In conclusion, FAB classification may predict outcome following transplantation in AML, NOS patients.
Subject: BONE-MARROW-TRANSPLANTATION
1ST COMPLETE REMISSION
ACUTE PROMYELOCYTIC LEUKEMIA
INTERNAL TANDEM DUPLICATION
PROGNOSTIC-FACTORS
HEMATOPOIETIC TRANSPLANTATION
FLT3/ITD-POSITIVE AML
EUROPEAN LEUKEMIANET
ONCOLOGY-GROUP
RECOMMENDATIONS
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Canaani_et_al_2 ... _Journal_of_Hematology.pdf 655.3Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record